Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Soon Yong | - |
dc.contributor.author | Kang, Woong Chol | - |
dc.contributor.author | Oh, Pyung Chun | - |
dc.contributor.author | Choi, Hanul | - |
dc.contributor.author | Moon, Chan Il | - |
dc.contributor.author | Lee, Kyounghoon | - |
dc.contributor.author | Han, Seung Hwan | - |
dc.contributor.author | Ahn, Taehoon | - |
dc.contributor.author | Choi, In Suck | - |
dc.contributor.author | Shin, Eak Kyun | - |
dc.date.available | 2020-02-28T16:43:43Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-09 | - |
dc.identifier.issn | 0910-8327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12324 | - |
dc.description.abstract | There are limited data on the optimal antithrombotic therapy for patients with atrial fibrillation (AF) who undergoing coronary stenting. We reviewed 203 patients (62.6 % men, mean age 68.3 +/- 10.1 years) between 2003 and 2012, and recorded clinical and demographic characteristics of the patients. Clinical follow-up included major adverse cardiac and cerebrovascular events (MACCE) (cardiac death, myocardial infarction, target lesion revascularization, and stroke), stent thrombosis, and bleeding. The most commonly associated comorbidities were hypertension (70.4 %), diabetes mellitus (35.5 %), and congestive heart failure (26.6 %). Sixty-three percent of patients had stroke risk higher than CHADS(2) score 2. At discharge, dual-antiplatelet therapy (aspirin, clopidogrel) was used in 166 patients (81.8 %; Group I), whereas 37 patients (18.2 %) were discharged with triple therapy (aspirin, clopidogrel, warfarin; Group II). The mean follow-up period was 42.0 +/- 29.0 months. The mean international normalized ratio (INR) in group II was 1.83 +/- 0.41. The total MACCE was 16.3 %, with stroke in 3.4 %. Compared with the group II, the incidence of MACCE (2.7 % vs 19.3 %, P = 0.012) and cardiac death (0 % vs 11.4 %, P = 0.028) were higher in the group I. Major and any bleeding, however, did not differ between the two groups. In multivariate analysis, no warfarin therapy (odds ratio 7.8, 95 % confidence interval 1.02-59.35; P = 0.048) was an independent predictor of MACCE. By Kaplan-Meier survival analysis, warfarin therapy was associated with a lower risk of MACCE (P = 0.024). In patients with AF undergoing coronary artery stenting, MACCE were reduced by warfarin therapy without increased bleeding, which might be related to tighter control with a lower INR value. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | HEART AND VESSELS | - |
dc.subject | ANTIPLATELET THERAPY USE | - |
dc.subject | LONG-TERM OUTCOMES | - |
dc.subject | ORAL ANTICOAGULATION | - |
dc.subject | ANTITHROMBOTIC THERAPY | - |
dc.subject | INTERVENTION | - |
dc.subject | MANAGEMENT | - |
dc.subject | RISK | - |
dc.subject | IMPLANTATION | - |
dc.subject | PREVENTION | - |
dc.subject | EVENTS | - |
dc.title | Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000341915300002 | - |
dc.identifier.doi | 10.1007/s00380-013-0399-x | - |
dc.identifier.bibliographicCitation | HEART AND VESSELS, v.29, no.5, pp.578 - 583 | - |
dc.identifier.scopusid | 2-s2.0-84929515699 | - |
dc.citation.endPage | 583 | - |
dc.citation.startPage | 578 | - |
dc.citation.title | HEART AND VESSELS | - |
dc.citation.volume | 29 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Suh, Soon Yong | - |
dc.contributor.affiliatedAuthor | Kang, Woong Chol | - |
dc.contributor.affiliatedAuthor | Oh, Pyung Chun | - |
dc.contributor.affiliatedAuthor | Choi, Hanul | - |
dc.contributor.affiliatedAuthor | Moon, Chan Il | - |
dc.contributor.affiliatedAuthor | Lee, Kyounghoon | - |
dc.contributor.affiliatedAuthor | Han, Seung Hwan | - |
dc.contributor.affiliatedAuthor | Ahn, Taehoon | - |
dc.contributor.affiliatedAuthor | Choi, In Suck | - |
dc.contributor.affiliatedAuthor | Shin, Eak Kyun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Warfarin | - |
dc.subject.keywordAuthor | Percutaneous coronary intervention | - |
dc.subject.keywordAuthor | Stent | - |
dc.subject.keywordPlus | ANTIPLATELET THERAPY USE | - |
dc.subject.keywordPlus | LONG-TERM OUTCOMES | - |
dc.subject.keywordPlus | ORAL ANTICOAGULATION | - |
dc.subject.keywordPlus | ANTITHROMBOTIC THERAPY | - |
dc.subject.keywordPlus | INTERVENTION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | IMPLANTATION | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | EVENTS | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.